<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01093521</url>
  </required_header>
  <id_info>
    <org_study_id>35876</org_study_id>
    <secondary_id>US FDA 5R01FD003704</secondary_id>
    <nct_id>NCT01093521</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients</brief_title>
  <official_title>A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test the pharmacokinetics, safety, and tolerability
      of an intravenous infusion of a drug called Ganite (gallium nitrate) in patients with cystic
      fibrosis. We want to see this drug is safe and tolerable and to see if high levels of the
      drug are found in the sputum.

      Funding Source - Food and Drug Administration (FDA) Office of Orphan Products Development
      (OOPD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two center pharmacokinetic and safety dosing study of IV gallium nitrate (Ganite®)
      in cystic fibrosis (CF) patients. Eighteen subjects are planned. Each subject will be
      administered a single 5-day infusion of study medication (one of 2 doses). No placebo is
      used. Each subject will receive 5 days of continuous infusion of the experimental treatment.
      There will be two dosing cohorts (cohort 1: 100 mg/m2/day and cohort 2: 200 mg/m2/day).
      Cohort 2 will begin enrollment only after Data Safety Monitoring Committee (DSMC) safety
      review and approval of cohort 1 data. Study visits occur at baseline (day 1), day 3 (visit
      2), day 6 (visit 3), day 8 (visit 4), day 14 (visit 5), day 28 (visit 6), and day 56 (visit
      7).

      Screening data will be reviewed to determine subject eligibility. Subjects who meet all
      inclusion criteria and none of the exclusion criteria will be entered into the study.

      The following treatment regimens will be used:

      • Experimental treatment continuous infusion of gallium nitrate at the following doses cohort
      1: 100 mg/m2/day and cohort 2: 200 mg/m2/day All subjects who receive at least one dose of
      study medication will be considered evaluable for safety and efficacy analyses. Incidence of
      adverse events will be monitored during the trial.

      Primary endpoints will be assessment of pharmacokinetic and safety/tolerability data.

      Secondary efficacy assessments will be based on changes in lung function and sputum P.
      aeruginosa density in sputum.

      Total duration of subject participation will be five weeks. Total duration of the study is
      expected to be 20 months.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Assessment of a 5 Day Infusion of Gallium Nitrate (IV Ganite®)</measure>
    <time_frame>Day 1 at t=1, 2 and 6 hours, Day 3, Day 6 at t= 1, 2, 8, and 12, Day 14 and Day 28</time_frame>
    <description>To assess the summed area under the curves of a 5 day infusion of IV Ga from day 1 to day 28 at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.
To assess the safety of a 5 day infusion of IV Ga at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.
Safety and tolerability of 5 days of treatment with IV administered gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>56 days from starting dose</time_frame>
    <description>Safety as measured by serous adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Events When Study Drug Infusion Was Stopped Early</measure>
    <time_frame>6 days from starting dose</time_frame>
    <description>Tolerability as measured by adverse events of a 5 day continuous infusion of IV Gallium as assessed by stopping study drug infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Spirometry From Baseline to Day 8</measure>
    <time_frame>8 days</time_frame>
    <description>Change in spirometry as measured by FEV1 in liters from baseline to day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lung Function From Baseline to Day 15</measure>
    <time_frame>15 days from starting dose</time_frame>
    <description>Change in FEV1 in liters from baseline to day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spirometry From Baseline to Day 28</measure>
    <time_frame>28 days from starting dose</time_frame>
    <description>Change in lung function as measured by FEV1 in liters from baseline to day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spirometry From Baseline to Day 56</measure>
    <time_frame>56 days from starting dose</time_frame>
    <description>Change in lung function as measured by FEV1 in liters from baseline to day 56</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Spirometry as Measured by FVC From Baseline to Day 8</measure>
    <time_frame>8 days from starting dose</time_frame>
    <description>Change from baseline in lung function assessed by FVC in liters after treatment with IV Ga at day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in P. Aeruginosa Density From Baseline to Day 8</measure>
    <time_frame>8 days from starting dose</time_frame>
    <description>Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sputum P. Aeruginosa Density From Baseline to Day 15</measure>
    <time_frame>15 days from starting dose</time_frame>
    <description>Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in P. Aeruginosa Density From Baseline to Day 56</measure>
    <time_frame>56 days from starting dose</time_frame>
    <description>Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 56</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>100 mg/m2 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five day continuous IV Gallium Nitrate (Ganite®) infusion at 100 mg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg/m2 dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five day continuous IV Gallium Nitrate (Ganite®) infusion at 200 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg/m2 dose</intervention_name>
    <description>5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day</description>
    <arm_group_label>100 mg/m2 dose</arm_group_label>
    <other_name>Ganite®</other_name>
    <other_name>gallium nitrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg/m2 dose</intervention_name>
    <description>5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day</description>
    <arm_group_label>200 mg/m2 dose</arm_group_label>
    <other_name>Ganite®</other_name>
    <other_name>gallium nitrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male or female, between 18 and 55 years of age

          2. Documented chronic colonization with Pseudomonas Aeruginosa (Pa)

          3. Confirmed diagnosis of CF:

               1. Documented history of &gt; 60 mmol/L chloride concentration in pilocarpine sweat
                  chloride test And/Or

               2. Genotype with two identifiable mutations consistent with CF, accompanied by one
                  or more phenotypic features consistent with diagnosis of CF

          4. Forced expiratory volume in the first second (FEV1) ≥ 30% of predicted value

          5. Able to expectorate sputum

          6. Serum liver function tests ≤ 2.5 x upper limit of normal

          7. Serum urea nitrogen (BUN) and creatinine ≤ 1.5 x upper limit of normal

          8. Serum creatinine ≤ 2.0 mg/dl

          9. Hemoglobin ≥ 9 g/dl, platelets ≥ 100,000/mm3, and white blood cells (WBC) ≥ 4,500/mm3
             and ≤ 15,000/mm3

         10. Ionized calcium ≥ the lower limit of normal

         11. Able to understand and sign the informed consent document, communicate with the
             Investigator, and comply with the requirements of the protocol

         12. If female and of childbearing potential, must have a negative pregnancy test on Day 1
             prior to receiving study drug

         13. If female and of childbearing potential, is willing to use adequate contraception, as
             determined by the investigator, for the duration of the study

        Exclusion Criteria:

          1. Acute pulmonary exacerbation requiring antibiotic intervention within 2 weeks prior to
             screening

          2. Osteoporosis defined as the most recent dexa scan within the prior 5 years with a
             T-score ≤ -2.5

          3. Pregnant or lactating female

          4. Known sensitivity to gallium

          5. Use of biphosphonates

          6. Use of any investigational drug and/or participated in any clinical trial within 3
             months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher H Goss, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2010</study_first_posted>
  <results_first_submitted>September 15, 2014</results_first_submitted>
  <results_first_submitted_qc>December 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2016</results_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Chris Goss</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>IV Gallium</keyword>
  <keyword>Gallium</keyword>
  <keyword>Ganite</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Gallium Infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium nitrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited in the Adult cystic fibrosis clinics at 3 centers (the University of Washington, University of Iowa, John's Hopkins University) from the second quarter 2010 and closed February 1, 2012. The study had two dosing cohorts. Cohort 1 completed enrollment in February, 2011. Cohort 2 completed enrollment on February 1, 2012.</recruitment_details>
      <pre_assignment_details>We employed no run-in period. No subjects withdrew after randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IV Gallium (Ganite®) Infusion</title>
          <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients were adults age 18 years but less than 55 years of age with CF and chronic Pseudomonal infection. Patient had to have a baseline FEV1% of predicted greater than or equal to 30%. They had to have been at least 14 days from the end of treatment with intravenous antibiotics for exacerbation. They could not be lactating or pregnant.</population>
      <group_list>
        <group group_id="B1">
          <title>IV Gallium (Ganite®) Infusion</title>
          <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume in one second (FEV1) (in liters)</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.25" lower_limit="1.06" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced vital capacity (FVC)(in liters)</title>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.60" lower_limit="1.84" upper_limit="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Pseudomonas aeruginosa quantitative sputum culture (CFU's/gr of sputum)</title>
          <units>Million CFU/gr of sputum</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116.7" lower_limit="0.378" upper_limit="866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Assessment of a 5 Day Infusion of Gallium Nitrate (IV Ganite®)</title>
        <description>To assess the summed area under the curves of a 5 day infusion of IV Ga from day 1 to day 28 at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.
To assess the safety of a 5 day infusion of IV Ga at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.
Safety and tolerability of 5 days of treatment with IV administered gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day.</description>
        <time_frame>Day 1 at t=1, 2 and 6 hours, Day 3, Day 6 at t= 1, 2, 8, and 12, Day 14 and Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day</description>
          </group>
          <group group_id="O2">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Assessment of a 5 Day Infusion of Gallium Nitrate (IV Ganite®)</title>
          <description>To assess the summed area under the curves of a 5 day infusion of IV Ga from day 1 to day 28 at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.
To assess the safety of a 5 day infusion of IV Ga at two doses: 100 mg/m2/day in adult subjects with CF; 200 mg/m2/day in adult subjects with CF.
Safety and tolerability of 5 days of treatment with IV administered gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day.</description>
          <units>ug*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503" spread="98"/>
                    <measurement group_id="O2" value="537" spread="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Spirometry From Baseline to Day 8</title>
        <description>Change in spirometry as measured by FEV1 in liters from baseline to day 8</description>
        <time_frame>8 days</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spirometry From Baseline to Day 8</title>
          <description>Change in spirometry as measured by FEV1 in liters from baseline to day 8</description>
          <population>ITT</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lung Function From Baseline to Day 15</title>
        <description>Change in FEV1 in liters from baseline to day 15</description>
        <time_frame>15 days from starting dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lung Function From Baseline to Day 15</title>
          <description>Change in FEV1 in liters from baseline to day 15</description>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Spirometry From Baseline to Day 28</title>
        <description>Change in lung function as measured by FEV1 in liters from baseline to day 28</description>
        <time_frame>28 days from starting dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spirometry From Baseline to Day 28</title>
          <description>Change in lung function as measured by FEV1 in liters from baseline to day 28</description>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Spirometry From Baseline to Day 56</title>
        <description>Change in lung function as measured by FEV1 in liters from baseline to day 56</description>
        <time_frame>56 days from starting dose</time_frame>
        <population>all those subjects enrolled after the amendment to add a day 56 (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spirometry From Baseline to Day 56</title>
          <description>Change in lung function as measured by FEV1 in liters from baseline to day 56</description>
          <population>all those subjects enrolled after the amendment to add a day 56 (ITT)</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Spirometry as Measured by FVC From Baseline to Day 8</title>
        <description>Change from baseline in lung function assessed by FVC in liters after treatment with IV Ga at day 8</description>
        <time_frame>8 days from starting dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Spirometry as Measured by FVC From Baseline to Day 8</title>
          <description>Change from baseline in lung function assessed by FVC in liters after treatment with IV Ga at day 8</description>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in P. Aeruginosa Density From Baseline to Day 8</title>
        <description>Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 8</description>
        <time_frame>8 days from starting dose</time_frame>
        <population>All available specimens</population>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in P. Aeruginosa Density From Baseline to Day 8</title>
          <description>Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 8</description>
          <population>All available specimens</population>
          <units>colony counts in millions per gm sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="297.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sputum P. Aeruginosa Density From Baseline to Day 15</title>
        <description>Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 15</description>
        <time_frame>15 days from starting dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sputum P. Aeruginosa Density From Baseline to Day 15</title>
          <description>Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 15</description>
          <units>colony counts in millions per gm sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="217.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in P. Aeruginosa Density From Baseline to Day 56</title>
        <description>Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 56</description>
        <time_frame>56 days from starting dose</time_frame>
        <population>All available specimens</population>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in P. Aeruginosa Density From Baseline to Day 56</title>
          <description>Change in sputum microbiology (specifically P. aeruginosa density based on quantitative cultures) from baseline to day 56</description>
          <population>All available specimens</population>
          <units>colony counts in millions per gm sputum</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.0" spread="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Serious Adverse Events</title>
        <description>Safety as measured by serous adverse events</description>
        <time_frame>56 days from starting dose</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events</title>
          <description>Safety as measured by serous adverse events</description>
          <population>ITT</population>
          <units>Serious Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Events When Study Drug Infusion Was Stopped Early</title>
        <description>Tolerability as measured by adverse events of a 5 day continuous infusion of IV Gallium as assessed by stopping study drug infusion</description>
        <time_frame>6 days from starting dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Gallium (Ganite®) Infusion</title>
            <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events When Study Drug Infusion Was Stopped Early</title>
          <description>Tolerability as measured by adverse events of a 5 day continuous infusion of IV Gallium as assessed by stopping study drug infusion</description>
          <units>Number of times study drug interupted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>56 days</time_frame>
      <desc>At study visits, all body systems were assessed for adverse events. Serious adverse events were assessed at all study visits and participants were told to inform their research team of any serious adverse events occurring between study visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>IV Gallium (Ganite®) Infusion</title>
          <description>Five day continuous IV Gallium (Ganite®)infusion
IV Gallium Nitrate (Ganite®) infusion: 5 day infusion of gallium nitrate (IV Ganite®) at a doses of 100 mg/m2/day and 200 mg/m2/day and 5 day infusion of gallium nitrate (IV Ganite®) 100 mg/m2/day and 200 mg/m2/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <description>Lymphadenopathy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic fibrosis lung</sub_title>
                <description>Cystic fibrosis lung exacerbation</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <description>otitis externa</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <description>Abdominal distension</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <description>Abdominal pain</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gastrointestinal reflux disease</sub_title>
                <description>Gastrointestinal reflux disease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <description>Stomach discomfort</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <description>vomiting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <description>fatigue</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <description>peripheral edema</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <description>fever</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <description>urinary tract infection</description>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>infusion site bruising</sub_title>
                <description>infusion site bruising</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>infusion site hematoma</sub_title>
                <description>infusion site hematoma</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>infusion site pain</sub_title>
                <description>infusion site pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>infusion site swelling</sub_title>
                <description>infusion site swelling</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <description>increased blood glucose</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Back pain</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <description>Gout</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <description>Muscle spasms</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>neck stiffness</sub_title>
                <description>Neck stiffness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <description>Pain in extremity</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>dizziness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <description>headache</description>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <description>Migraine headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>albuminuria</sub_title>
                <description>albuminuria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <description>Pyuria</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <description>Pelvic pain</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <description>increased cough</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>crackles lung</sub_title>
                <description>Crackles heard on lung exam</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <description>Dyspnoea</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <description>Haemoptysis</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>Nasal congestion</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <description>Epistaxis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>Non-cardiac chest pain</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <description>Productive cough</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <description>rhinitis</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>sinus congestion</sub_title>
                <description>sinus congestion</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <description>Sinus disorder</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sputum discolored</sub_title>
                <description>sputum discolored</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <description>Throat irritation</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>Upper respiratory tract infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <description>Voice alteration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>Rash</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary limitation of our study was that it was uncontrolled without a blinded placebo. Thus, subjective endpoints could have been biased by either the subjects or the investigators.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-543-3166</phone>
      <email>goss@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

